Comparison 8. Mefloquine (MQ) versus daily cotrimoxazole (CTXp).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
8.1 Maternal peripheral parasitaemia at delivery (polymerase chain reaction)	1	98	Risk Ratio (M‐H, Fixed, 95% CI)	0.21 [0.03, 1.72]
8.2 Maternal anaemia at delivery	1	100	Risk Ratio (M‐H, Fixed, 95% CI)	0.90 [0.26, 3.16]
8.3 Placental malaria (polymerase chain reaction)	1	94	Risk Ratio (M‐H, Fixed, 95% CI)	0.73 [0.13, 4.15]
8.4 Placental malaria (blood smear)	1	108	Risk Ratio (M‐H, Fixed, 95% CI)	0.35 [0.01, 8.30]
8.5 Maternal haemoglobin level at delivery (in g/dL)	1	100	Mean Difference (IV, Fixed, 95% CI)	‐0.10 [‐0.67, 0.47]
8.6 Low birth weight (< 2500 g)	1	120	Risk Ratio (M‐H, Fixed, 95% CI)	1.52 [0.56, 4.13]
8.7 Mean birth weight (in grams)	1	120	Mean Difference (IV, Fixed, 95% CI)	‐102.00 [‐255.52, 51.52]
8.8 Cord blood parasitaemia	1	140	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
8.9 Prematurity	1	125	Risk Ratio (M‐H, Fixed, 95% CI)	1.08 [0.33, 3.56]
8.10 SAEs during pregnancy	1	140	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [0.28, 4.07]
8.11 Spontaneous abortion	1	139	Risk Ratio (M‐H, Fixed, 95% CI)	1.07 [0.07, 16.84]
8.12 Stillbirth	1	139	Risk Ratio (M‐H, Fixed, 95% CI)	4.30 [0.49, 37.49]
8.13 Congenital malformations	1	139	Risk Ratio (M‐H, Fixed, 95% CI)	0.54 [0.05, 5.79]
8.14 Maternal mortality	1	139	Odds Ratio (M‐H, Fixed, 95% CI)	Not estimable
8.15 Early neonatal mortality (< 7 days)	1	129	Risk Ratio (M‐H, Fixed, 95% CI)	1.05 [0.07, 16.39]
8.16 Infant mortality (≥ 7 days up to 6 weeks of age)	1	129	Risk Ratio (M‐H, Fixed, 95% CI)	2.10 [0.19, 22.54]
8.17 Adverse events: headache	1	139	Risk Ratio (M‐H, Fixed, 95% CI)	0.21 [0.01, 4.39]
8.18 Adverse events: vomiting	1	139	Risk Ratio (M‐H, Fixed, 95% CI)	13.43 [3.31, 54.54]
8.19 Adverse events: dizziness	1	139	Risk Ratio (M‐H, Fixed, 95% CI)	52.60 [3.26, 848.24]
8.20 Adverse events: fatigue/weakness	1	139	Risk Ratio (M‐H, Fixed, 95% CI)	6.99 [1.64, 29.81]